MedMen Enterprises, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of MedMen Enterprises, Inc. in twelve months, the latest record being from 4 October 2023.
Over the whole record (from 2020), the tally stands at no purchases and 24 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended June 2022 · cache
25 of 65 declarations
MedMen Enterprises, Inc. is a U.S.-based cannabis retail company built around a premium dispensary concept and consumer-facing brand positioning. The company is associated with the MMNFF ticker, and while investors may loosely place it in the broader NYSE/NASDAQ universe, its more recent market reality has been defined less by normal listed-company execution and more by compliance, reporting, and regulatory issues. MedMen was founded in 2010 and developed its identity as one of the more recognizable names in the legal cannabis retail space, emphasizing a polished store experience, product education, and convenience for both recreational customers and, where applicable, wellness-oriented use cases. Its headquarters and operational address are in Los Angeles, California, United States.
Operationally, MedMen focuses on cannabis retail and related consumer products. Its store model has historically included flower, pre-rolls, vapes, edibles, topicals, and other wellness-oriented products, with the company positioning itself as a curated, high-touch retailer rather than a commodity seller. MedMen has also highlighted omnichannel features such as online browsing, in-store pickup, and delivery in selected markets. The company has said it offers a broad assortment of products and a guided shopping experience, which has been central to its brand differentiation in an industry where customer experience and regulatory licensing often matter as much as product breadth.
From a competitive standpoint, MedMen has sought to be a flagship retail brand in the U.S. legal cannabis sector rather than merely a back-office operator. Its publicly promoted footprint has centered on Los Angeles locations, including West Hollywood, Downtown Los Angeles, and LAX, with earlier disclosures also indicating operations in other states such as Nevada, Illinois, Arizona, Massachusetts, Florida, and New York. For equity investors, that geographic spread has to be viewed through the lens of licensing complexity, state-by-state regulation, and capital intensity, all of which have been structural challenges for cannabis operators in the United States.
Recent developments are especially important and largely adverse. SEC materials in 2025 and 2026 point to administrative enforcement activity, delinquent filings, and a 2026 revocation of Exchange Act registration. In practical terms, that sharply reduces the usefulness of standard public-market analysis because disclosure quality and trading transparency have weakened. The company’s recent public record therefore suggests a situation dominated by regulatory and compliance risk rather than expansionary operating momentum. In summary, MedMen is a U.S. cannabis retailer founded in 2010, headquartered in Los Angeles, known for premium dispensary branding, but currently best understood through its governance, reporting, and regulatory headwinds rather than through growth metrics or market-share leadership.